BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $10.52 million. The enterprise value is $4.55 million.

Market Cap	10.52M
Enterprise Value	4.55M

Important Dates

The next estimated earnings date is Tuesday, May 26, 2026, before market open.

Earnings Date	May 26, 2026
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.61 billion shares outstanding. The number of shares has increased by 105.76% in one year.

Current Share Class	n/a
Shares Outstanding	2.61B
Shares Change (YoY)	+105.76%
Shares Change (QoQ)	+2.12%
Owned by Insiders (%)	0.39%
Owned by Institutions (%)	3.97%
Float	2.50B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.91
Forward PS	n/a
PB Ratio	0.45
P/TBV Ratio	5.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.43.

Current Ratio	1.95
Quick Ratio	1.76
Debt / Equity	0.43
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-8.22

Financial Efficiency

Return on equity (ROE) is -11.01% and return on invested capital (ROIC) is -20.74%.

Return on Equity (ROE)	-11.01%
Return on Assets (ROA)	-16.11%
Return on Invested Capital (ROIC)	-20.74%
Return on Capital Employed (ROCE)	-35.74%
Weighted Average Cost of Capital (WACC)	8.29%
Revenue Per Employee	$49,167
Profits Per Employee	-$48,958
Employee Count	24
Asset Turnover	0.03
Inventory Turnover	0.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.46% in the last 52 weeks. The beta is 0.48, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.48
52-Week Price Change	-16.46%
50-Day Moving Average	2.53
200-Day Moving Average	3.28
Relative Strength Index (RSI)	63.99
Average Volume (20 Days)	18,127

Short Selling Information

The latest short interest is 154,748, so 3.56% of the outstanding shares have been sold short.

Short Interest	154,748
Short Previous Month	163,818
Short % of Shares Out	3.56%
Short % of Float	n/a
Short Ratio (days to cover)	8.90

Income Statement

In the last 12 months, BioLineRx had revenue of $1.18 million and -$1.18 million in losses. Loss per share was -$0.00.

Revenue	1.18M
Gross Profit	950,000
Operating Income	-10.29M
Pretax Income	-2.03M
Net Income	-1.18M
EBITDA	-10.06M
EBIT	-10.29M
Loss Per Share	-$0.00

Full Income Statement

Balance Sheet

The company has $20.88 million in cash and $10.15 million in debt, giving a net cash position of $10.73 million or $0.00 per share.

Cash & Cash Equivalents	20.88M
Total Debt	10.15M
Net Cash	10.73M
Net Cash Per Share	$0.00
Equity (Book Value)	23.35M
Book Value Per Share	0.01
Working Capital	11.56M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$8.07 million and capital expenditures -$25,000, giving a free cash flow of -$8.10 million.

Operating Cash Flow	-8.07M
Capital Expenditures	-25,000
Depreciation & Amortization	227,000
Net Borrowing	-5.01M
Free Cash Flow	-8.10M
FCF Per Share	-$0.00

Full Cash Flow Statement

Margins

Gross margin is 80.51%, with operating and profit margins of -871.78% and -99.58%.

Gross Margin	80.51%
Operating Margin	-871.78%
Pretax Margin	-171.69%
Profit Margin	-99.58%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-105.76%
Shareholder Yield	-105.76%
Earnings Yield	-11.17%
FCF Yield	-77.01%

Analyst Forecast

The average price target for BioLineRx is $19.00, which is 622.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$19.00
Price Target Difference	622.43%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.

Last Split Date	Jan 30, 2025
Split Type	Reverse
Split Ratio	1:40

Scores

BioLineRx has an Altman Z-Score of -13.64 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.64
Piotroski F-Score	3